The Evolution Of 21st Century Cures Legislation

Final version of Cures legislation combines several aspects of initial House and Senate legislation, and also includes some completely new elements.

The long-awaited, mutually-agreed upon 21st Century Cures bill has finally been set in motion to become law, as the House is scheduled to vote on the biomedical innovation legislation Nov. 30.

The new legislation released by leaders of the House Energy and Commerce Committee and Senate Health, Education, Labor and Pensions (HELP) Committee consolidates into a single bill various drug development elements unique to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Pink Sheet

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.